Urumbaev R K, Suprunova I P, Imanakunova D Sh, Rakhimova G R
Kardiologiia. 1992 Mar;32(3):48-50.
The antiarrhythmic agent mexicord (Polfa, Poland) versus ethmozine underwent a clinical trial. Meticord was found to have a marked antiarrhythmic effect and be useful in the long-term management of patients with ventricular tachyarrhythmias.